http://mapk-inhibitors.com/ene....rgetic-kinetic-solut
PROTACs hijack the catalytic activity of ubiquitin E3 ligases to mediate proteasome centered degradation of chosen protein of great interest (POI), by taking the ligase and POI into close spatial proximity and initiating the poly-ubiquitination process. When compared to traditional small-molecule medications, PROTACs lower the issues of dosage, medicine resistance, side-effects and undruggable goals that may not be focused pharmacolog
Like
Comment
Share
